Accriva Diagnostics, Inc. recalls Hemochron Jr.
- Published
- 11 Nov 2026
- Units affected
- 28710
- Agency
- FDA
- Country
- United States
The hazard
Microcoagulation test used to evaluate low dose heparin anticoagulation has a mispositioned or absent clot activating reagent, which may result in out-of-range high error code, or erroneously high results, which may lead retest, or overestimation of patient's anticoagulation, leading to inadequate anticoagulant therapy, which could result in thrombosis.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Contact your doctor, clinic or the device maker to find out if your device is affected and what to do next. Do not stop using a life-supporting device without medical advice.
- Check the model and lot or serial number on the device label.
- Speak to your doctor or the clinic that supplied the device before stopping use.
Product details
Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time (APTT) Test Cuvette, REF: J103
- Brand / company
- Accriva Diagnostics, Inc.
- Codes / lots
- UDI-DI: 10711234103012, Lot(Expiration): B6JCA005(02/28/2027), C6JCA008(03/31/2027), D6JCA011(04/30/2027), K5JCA041(10/31/2026), C6JCA007(03/31/2027)
- Distribution
- Worldwide - US Nationwide distribution in the states of MA, MO, AK, WV, NJ, TX, VA, IL, NY and the countries of China, Colombia.
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 11 Nov 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.